- Initiation of a Phase II trial in multiple myeloma evaluating the combination of IPH 2101 - a fully human anti-KIR monoclonal antibody stimulating NK cells' anti-tumoral activity, with Celgene’s REVLIMID®
- Growing body of evidence in hematological malignancies supports REVLIMID® enhanced NK-mediated cytotoxicity and its potential synergy with IPH 2101’s mechanism of action
| PR in english | 47.47 KB |
| CP en français | 50 KB |